United Kingdom (UK)
Recombinant monoclonal antibody to CD146. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma ABX-MA1 (3.19.1).
UniProt Accession Number of Target Protein: P43121
Alternative Name(s) of Target: MCAM; MUC18; Mel-CAM; cell surface glycoprotein MUC18; cell surface glycoprotein P1H12; melanoma cell adhesion molecule; melanoma-associated antigen A32; melanoma-associated antigen MUC18; S-endo 1 endothelial-associated antigen; c3.19.1
Immunogen: The original antibody was generated by immunizing XenoMouse® mice with SK-MEL-28 cells admixed 1:1 v/v with Complete Freund's Adjuvant (CFA), followed by four injections with 5 μg soluble MUC18-human IgG2 Fc fusion protein admixed 1:1 v/v with Incomplete Freund's Adjuvant (IFA) and then a final boost of 10 μg soluble MUC18-human IgG2 Fc fusion protein without adjuvant.
Specificity: This antibody binds human CD146 (MCAM/MUC18). CD146 is a cell-surface glycoprotein composed of a signal peptide, five immunoglobulin-like domains, a transmembrane region, and a short cytoplasmic tail . Its expression is associated with tumor progression and the development of metastatic potential.
Application Notes: A number of studies have identified MUC18 as a marker of tumor progression and metastasis in melanomas (PMID: 2602381; 3542195; 8162602). The binding specificity of the human IgG2 version of this antibody for human CD146 was checked using ELISA. The original human IgG2 version of this antibody was also able to detect MUC18 expressed on melanoma cell lines like A375SM, TXM-13 and WM-2664 in a western blot assay. The human IgG2 version was also able to identify native MUC18 expression on A375-SM and WM-2664 cells in a flow cytometric assay (PMID: 12208768; US6924360). ABX-MA1 had no effect on melanoma cell proliferation rate in vitro. ABX-MA1 treatment of melanoma cells in vitro significantly inhibited the promoter and collagenase activity of matrix metalloproteinase 2, resulting in decreased invasion through Matrigel-coated filters. ABX-MA1 inhibited tumor growth in nude mice injected with metastatic melanoma lines A375SM and WM2664. ABX-MA1 also disrupted spheroid formation by melanoma cells expressing MUC18 (homotypic interaction) and the ability of these cells to attach to human vascular endothelial cells [HUVECs (MUC18 positive)] in vitro. ABX-MA1 treatment also suppressed experimental lung metastasis of these melanoma cells (PMID: 12208768). This antibody was also used in an in vitro and in vivo study of role of MUC18 in the metastasis of osteosarcoma (PMID: 14695161). A combination of ABX-MA1 and anti-IL-8 (ABX-IL8) was studied as model combinations for the treatment of melanoma (PMID: 16965268).
Antibody first published in:
Mills et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14. PMID:12208768
Note on publication:
Studies the effect of ABX-MA1 on angiogenesis, tumor growth and metastasis.